- Home
- CLCO vs ALLO Comparison
CLCO vs ALLO Comparison
Compare CLCO & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLCO
- ALLO
- Stock Information
- Founded
- CLCO 2018
- ALLO 2017
- Country
- CLCO United Kingdom
- ALLO United States
- Employees
- CLCO N/A
- ALLO N/A
- Industry
- CLCO
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CLCO
- ALLO Health Care
- Exchange
- CLCO Nasdaq
- ALLO Nasdaq
- Market Cap
- CLCO 353.6M
- ALLO 371.8M
- IPO Year
- CLCO N/A
- ALLO 2018
- Fundamental
- Price
- CLCO $6.08
- ALLO $1.17
- Analyst Decision
- CLCO
- ALLO Strong Buy
- Analyst Count
- CLCO 0
- ALLO 9
- Target Price
- CLCO N/A
- ALLO $8.44
- AVG Volume (30 Days)
- CLCO 112.0K
- ALLO 4.1M
- Earning Date
- CLCO 05-21-2025
- ALLO 05-13-2025
- Dividend Yield
- CLCO 9.85%
- ALLO N/A
- EPS Growth
- CLCO N/A
- ALLO N/A
- EPS
- CLCO 1.31
- ALLO N/A
- Revenue
- CLCO $320,759,000.00
- ALLO N/A
- Revenue This Year
- CLCO $2.03
- ALLO N/A
- Revenue Next Year
- CLCO N/A
- ALLO $10.02
- P/E Ratio
- CLCO $4.55
- ALLO N/A
- Revenue Growth
- CLCO N/A
- ALLO N/A
- 52 Week Low
- CLCO $4.51
- ALLO $0.86
- 52 Week High
- CLCO $13.15
- ALLO $3.78
- Technical
- Relative Strength Index (RSI)
- CLCO 51.28
- ALLO 44.54
- Support Level
- CLCO $5.91
- ALLO $1.02
- Resistance Level
- CLCO $6.21
- ALLO $1.15
- Average True Range (ATR)
- CLCO 0.22
- ALLO 0.11
- MACD
- CLCO -0.04
- ALLO 0.02
- Stochastic Oscillator
- CLCO 32.61
- ALLO 75.61
About CLCO Cool Company Ltd.
Cool Co Ltd is a LNG shipping company. The company is engaged in the acquisition, ownership, operation and chartering of liquefied natural gas (LNG) carriers (LNGCs), and the operation of third party fleets under management agreements. The company manages its business through a single operating and reporting segment, the LNG carrier market.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.